Sylvia Villeneuve1, Véronique Pepin2, Shady Rahayel3, Josie-Anne Bertrand4, Myriam de Lorimier5, Amanda Rizk2, Catherine Desjardins5, Simon Parenteau6, François Beaucage6, Steve Joncas7, Oury Monchi8, Jean-François Gagnon9. 1. Département de Psychologie, Université de Montréal, Montreal, QC; Centre de Recherche, Institut Universitaire de Gériatrie de Montréal, Montreal, QC; Centre de Recherche, Hôpital du Sacré-Coeur de Montréal, Montreal, QC. 2. Centre de Recherche, Hôpital du Sacré-Coeur de Montréal, Montreal, QC; Department of Exercise Science, Concordia University, Montreal, QC. 3. Centre de Recherche, Hôpital du Sacré-Coeur de Montréal, Montreal, QC; Département de Psychologie, Université du Québec à Montréal, Montreal, QC. 4. Département de Psychologie, Université de Montréal, Montreal, QC; Centre de Recherche, Hôpital du Sacré-Coeur de Montréal, Montreal, QC. 5. Centre de Recherche, Hôpital du Sacré-Coeur de Montréal, Montreal, QC. 6. Service de Pneumologie, Hôpital du Sacré-Coeur de Montréal, Montreal, QC. 7. Geriatric Rehabilitation Service, Bruyère Continuing Care, Ottawa, ON, Canada. 8. Département de Radiologie, Université de Montréal, Montreal, QC; Centre de Recherche, Institut Universitaire de Gériatrie de Montréal, Montreal, QC. 9. Centre de Recherche, Hôpital du Sacré-Coeur de Montréal, Montreal, QC; Département de Psychologie, Université du Québec à Montréal, Montreal, QC. Electronic address: gagnon.jean-francois.2@uqam.ca.
Abstract
BACKGROUND: Cognitive impairment is a frequent feature of COPD. However, the proportion of patients with COPD with mild cognitive impairment (MCI) is still unknown, and no screening test has been validated to date for detecting MCI in this population. The goal of this study was to determine the frequency and subtypes of MCI in patients with COPD and to assess the validity of two cognitive screening tests, the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA), in detecting MCI in patients with COPD. METHODS: Forty-five patients with moderate to severe COPD and 50 healthy control subjects underwent a comprehensive neuropsychologic assessment using standard MCI criteria. Receiver operating characteristic curves were obtained to assess the validity of the MMSE and the MoCA to detect MCI in patients with COPD. RESULTS: MCI was found in 36% of patients with COPD compared with 12% of healthy subjects. Patients with COPD with MCI had mainly the nonamnestic MCI single domain subtype with predominant attention and executive dysfunctions. The optimal MoCA screening cutoff was 26 (≤ 25 indicates impairment, with 81% sensitivity, 72% specificity, and 76% correctly diagnosed). No MMSE cutoff had acceptable validity. CONCLUSIONS: In this preliminary study, a substantial proportion of patients with COPD were found to have MCI, a known risk factor for dementia. Longitudinal follow-up on these patients is needed to determine the risk of developing more severe cognitive and functional impairments. Moreover, the MoCA is superior to the MMSE in detecting MCI in patients with COPD.
BACKGROUND:Cognitive impairment is a frequent feature of COPD. However, the proportion of patients with COPD with mild cognitive impairment (MCI) is still unknown, and no screening test has been validated to date for detecting MCI in this population. The goal of this study was to determine the frequency and subtypes of MCI in patients with COPD and to assess the validity of two cognitive screening tests, the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA), in detecting MCI in patients with COPD. METHODS: Forty-five patients with moderate to severe COPD and 50 healthy control subjects underwent a comprehensive neuropsychologic assessment using standard MCI criteria. Receiver operating characteristic curves were obtained to assess the validity of the MMSE and the MoCA to detect MCI in patients with COPD. RESULTS: MCI was found in 36% of patients with COPD compared with 12% of healthy subjects. Patients with COPD with MCI had mainly the nonamnestic MCI single domain subtype with predominant attention and executive dysfunctions. The optimal MoCA screening cutoff was 26 (≤ 25 indicates impairment, with 81% sensitivity, 72% specificity, and 76% correctly diagnosed). No MMSE cutoff had acceptable validity. CONCLUSIONS: In this preliminary study, a substantial proportion of patients with COPD were found to have MCI, a known risk factor for dementia. Longitudinal follow-up on these patients is needed to determine the risk of developing more severe cognitive and functional impairments. Moreover, the MoCA is superior to the MMSE in detecting MCI in patients with COPD.
Authors: Nicholas J Burgraff; Suzanne E Neumueller; Kirstyn Buchholz; Thomas M Langer; Matthew R Hodges; Lawrence Pan; Hubert V Forster Journal: J Physiol Date: 2018-10-14 Impact factor: 5.182
Authors: James H Meyers; Ruby Hickman; Ashley D Cristal; Pam Factor-Litvak; Stephanie Cosentino; Elan D Louis Journal: Parkinsonism Relat Disord Date: 2018-10-31 Impact factor: 4.891
Authors: Balwinder Singh; Michelle M Mielke; Ajay K Parsaik; Ruth H Cha; Rosebud O Roberts; Paul D Scanlon; Yonas E Geda; Teresa J Christianson; V Shane Pankratz; Ronald C Petersen Journal: JAMA Neurol Date: 2014-05 Impact factor: 18.302
Authors: David G Cohen; Jason D Christie; Brian J Anderson; Joshua M Diamond; Ryan P Judy; Rupal J Shah; Edward Cantu; Scarlett L Bellamy; Nancy P Blumenthal; Ejigayehu Demissie; Ramona O Hopkins; Mark E Mikkelsen Journal: Ann Am Thorac Soc Date: 2014-05
Authors: Seth N Levin; Alexandra M Hajduk; David D McManus; Chad E Darling; Jerry H Gurwitz; Frederick A Spencer; Robert J Goldberg; Jane S Saczynski Journal: Am Heart J Date: 2014-09-16 Impact factor: 4.749
Authors: Amanda M Brunette; Kristen E Holm; Frederick S Wamboldt; Elizabeth Kozora; David J Moser; Barry J Make; James D Crapo; Kimberly Meschede; Howard D Weinberger; Kerrie L Moreau; Russell P Bowler; Karin F Hoth Journal: J Clin Exp Neuropsychol Date: 2017-08-02 Impact factor: 2.475